1. Home
  2. KRRO vs IVVD Comparison

KRRO vs IVVD Comparison

Compare KRRO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$12.67

Market Cap

196.4M

Sector

Health Care

ML Signal

SELL

Logo Invivyd Inc.

IVVD

Invivyd Inc.

SELL

Current Price

$0.53

Market Cap

212.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KRRO
IVVD
Founded
2014
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.4M
212.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
KRRO
IVVD
Price
$12.67
$0.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
3
Target Price
★ $21.50
$10.00
AVG Volume (30 Days)
212.2K
★ 3.4M
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.02
EPS
N/A
★ N/A
Revenue
$6,392,000.00
★ $53,426,000.00
Revenue This Year
N/A
$12.40
Revenue Next Year
N/A
$44.85
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 181.46
110.47
52 Week Low
$5.20
$0.53
52 Week High
$17.35
$3.01

Technical Indicators

Market Signals
Indicator
KRRO
IVVD
Relative Strength Index (RSI) 48.28 38.22
Support Level $11.81 $0.53
Resistance Level $14.47 $0.66
Average True Range (ATR) 1.45 0.05
MACD -0.22 0.00
Stochastic Oscillator 24.60 11.68

Price Performance

Historical Comparison
KRRO
IVVD

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About IVVD Invivyd Inc.

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Share on Social Networks: